Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series

Tumors deficient in DNA mismatch repair are known to display increased susceptibility to immune checkpoint inhibitors due to accumulation of DNA damage and increased neoantigen load. This suggests that deficiency in the BRCA-related DNA repair mechanism may also be a surrogate marker for immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuo, Koji, Spragg, Samantha E., Ciccone, Marcia A., Blake, Erin A., Ricker, Charité, Pham, Huyen Q., Roman, Lynda D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038829/
https://www.ncbi.nlm.nih.gov/pubmed/29998185
http://dx.doi.org/10.1016/j.gore.2018.06.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038829/
https://www.ncbi.nlm.nih.gov/pubmed/29998185
http://dx.doi.org/10.1016/j.gore.2018.06.011

Ejemplares similares